01 Requirement
Recognize
HIV-associated infected-cell targets must be recognized with sufficient specificity to distinguish relevant reservoir-associated cells.
Project Detail
HIV Trispecific Antibody
A reservoir-directed trispecific antibody program focused on HIV-associated target recognition, immune engagement, and infected-cell clearance.
Overview
Beyond suppression toward reservoir-directed antibody clearance.
HIV can persist through latently infected cells and integrated proviral DNA that remain beyond the reach of viral suppression alone. Macro HRD's HIV program uses trispecific antibody logic to recognize HIV-associated targets and engage immune pathways against infected reservoir cells.
Global Burden
A continuing global health crisis.
Suppression has changed HIV care, but durable cure-directed strategies remain an unmet need.
39.9MPeople living with HIV globally.
1.5MNew infections occur annually.
630KAIDS-related deaths occur annually.
9.3MPeople remain without access to lifesaving treatment.
Problem Being Solved
The latent reservoir is the barrier current therapy does not fully remove.
The latent reservoir is the central barrier for cure-directed HIV work because infected cells can persist even when active viral replication is controlled.
02 Requirement
Engage
Immune effector pathways must be brought into productive proximity with infected-cell targets.
03 Requirement
Co-Stimulate
Co-stimulatory logic may support immune activation and effector function where target engagement is achieved.
04 Requirement
Clear
The development goal is immune-mediated infected-cell clearance.
Scientific Approach
Reservoir-directed antibody logic.
The program is antibody-led and distinct from AH-D peptide biology or optional LNP formulation work.
HIV Env Recognition
Bind infected-cell targets
An HIV-targeting arm, such as broadly neutralizing Env recognition logic, supports binding to HIV-associated infected-cell targets.
T Cell Engagement
Redirect immune effectors
CD3 engagement may redirect T cells toward infected-cell clearance where target engagement is achieved.
Co-Stimulatory Support
Support effector function
CD28 co-stimulatory logic may support immune activation and effector function.
Reservoir-Directed Clearance
Clear infected cells
The strategy is evaluated for immune-mediated clearance in reservoir-relevant contexts.
Mechanism of Action
Conceptual trispecific antibody architecture for HIV reservoir-directed clearance.
The mechanism is described through HIV Env-binding or bNAb logic, CD3 engagement, and CD28 co-stimulation.
01
HIV-Associated Target Recognition
Env-binding or broadly neutralizing antibody logic is used conceptually to recognize HIV-associated infected-cell targets.
02
CD3 Immune Engagement
CD3 engagement may recruit T cell activity toward infected-cell clearance after target binding.
03
CD28 Co-Stimulation
CD28 logic may provide co-stimulatory support for immune activation and effector function.
04
Reservoir-Directed Objective
The program is evaluated for infected-cell clearance in reservoir-relevant biology.
Supporting Analysis
GEDM3DQ supports program modeling, not the therapeutic mechanism.
GEDM3DQ may support program modeling, decision logic, and development planning. Therapeutic claims remain grounded in biological validation.
Modeling
State and uncertainty analysis
Structured modeling can help compare development paths and biological assumptions.
Evaluation
Evidence organization
Decision logic can support how the program evaluates assay outputs, construct performance, and validation priorities.
Planning
Development planning
GEDM3DQ can support planning discussions while experimental and clinical validation remain required.
Capabilities
Target recognition, immune engagement, co-stimulation, and reservoir-directed clearance.
The program capabilities are organized around an antibody-led reservoir strategy. Delivery technologies may be evaluated as supporting tools where appropriate.
01 Capability
HIV Env Recognition
Broadly neutralizing Env recognition logic can support binding to HIV-associated infected-cell targets.
02 Capability
Immune Engagement
CD3 engagement may redirect T cells toward infected-cell targets after binding.
03 Capability
Co-Stimulatory Logic
CD28 co-stimulation may support effector activation and function where target engagement is achieved.
04 Capability
Supportive Delivery Evaluation
Advanced LNP or other delivery strategies may be evaluated for reservoir-tissue exposure where formulation adds value.
Evidence
Published scientific rationale and Macro HRD program status are separate.
Published N6, trispecific, SHIV, and related literature supports the scientific rationale, while Macro HRD-owned development progress is presented separately through program-specific disclosures.
Published Scientific Rationale
Trispecific and bNAb literature
Background HIV antibody literature supports the rationale for combining HIV-associated target recognition with immune engagement and co-stimulatory logic.
Published Scientific Rationale
Reservoir biology
HIV persistence literature supports the focus on latently infected cells and integrated proviral DNA rather than free virus alone.
Macro HRD Program Status
Program disclosure
Future updates will follow disclosed construct, assay, or milestone evidence.
Development Dependency
Reservoir-tissue delivery
Delivery to relevant reservoir tissues remains an important development consideration for future program evaluation.
Platform Connections
Connected capabilities supporting the HIV antibody program.
The HIV program is led by trispecific antibody logic. Other technologies are supporting tools only where they add modeling, delivery, or development value.
HIV Trispecific Antibody
HIV-associated target recognition combined with CD3 engagement and CD28 co-stimulatory logic.
Advanced LNP Blood–Brain Barrier Crossing Lipid Nanoparticle Delivery Platform
Optional formulation evaluation for exposure and reservoir-tissue access where appropriate.
Published Rationale
Background literature is presented separately from Macro HRD-owned program milestones.
GEDM3DQ Decision Engine
Program modeling and development-planning support alongside biological validation.
Development and Partnerships
Global partners and high-burden target populations.
Scientific and translational relationships are presented through approved public disclosures.
Target populations include high-burden settings where HIV remains a major clinical and public-health challenge.
Program Quote
Reservoir-directed antibody development requires biological validation at each step.
The HIV program frames the cure challenge around infected-cell recognition, immune engagement, and reservoir-directed clearance, with published scientific rationale kept separate from Macro HRD-owned program milestones.